PDZK1IP1 and chronic obstructive pulmonary disease: Interestingly, the finding that MAP17 is associated with a variety of inflammatory diseases such as Crohn’s disease, COPD and psoriasis provides an avenue to test bortezomib as an effective inhibitor of these chronic inflammatory diseases.